Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin’s Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China

Table 3

Multivariate Cox regression analysis.

Variable	PFS		OS
	HR (95%CI)	p value	HR (95%CI)	p value
Sex (female vs. male)
Age (≤60 vs. >60)
Type (B-cell associated indolent lymphoma vs. Mantle cell lymphoma)	2.645 (0.995-7.026)	0.051
Stage (I-II stage vs. III-IV stage)
ECOG PS (0-1 vs. ≥2)
Number of treatment lines (first-line vs. ≥second-line or later)
β2-MG (>3.5 mg/L vs. ≤3.5 mg/L)

OS. HR (95%CI). value.